Democrat’s drug pricing manifesto hints at a carveout for small biotechs

WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is promising that his signature drug pricing package won’t eviscerate small biotech companies.

Wyden, typically a fierce critic of the drug industry, is suddenly giving a shoutout to small biotech companies and their role in developing “groundbreaking new treatments.”  He’s even promising that the package he is crafting “can be tailored to the scale of these companies, as well as other factors that affect their access to capital.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Source link


The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button